BRM Immunotherapy of Orthotopically Implanted Murine Bladder Tumours: Treatment Response by Monitoring MRI
The authors evaluated magnetic resonance imaging (MRI) for monitoring orthotopic bladder tumour growth and treatment response to intravesical immunotherapy with the biological response modifiers (BRMs): recombinant tumour necrosis factor alpha (TNF-α), combination of TNF-α plus interferon gamma (IFN...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1992-01-01
|
| Series: | Canadian Journal of Infectious Diseases |
| Online Access: | http://dx.doi.org/10.1155/1992/510914 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567378821513216 |
|---|---|
| author | Salam A Kadhim Joseph L Chin Bertha M Garcia Peeyush K Lala Chris J Norley Barbara A McLean Stephen J Karlik |
| author_facet | Salam A Kadhim Joseph L Chin Bertha M Garcia Peeyush K Lala Chris J Norley Barbara A McLean Stephen J Karlik |
| author_sort | Salam A Kadhim |
| collection | DOAJ |
| description | The authors evaluated magnetic resonance imaging (MRI) for monitoring orthotopic bladder tumour
growth and treatment response to intravesical immunotherapy with the biological response modifiers
(BRMs): recombinant tumour necrosis factor alpha (TNF-α), combination of TNF-α plus interferon gamma
(IFN-γ) and interleukin-2 (IL-2). MRI demonstrated detection of early superficial murine bladder tumour
(MBT-2) and accurate sequential assessment of the topography and depth of intravesical tumour involvement.
Response to intravesical instillations with multiple doses ofBRMs was assessed against early stage
MBT-2 bladder tumours (confirmed by MRI) 14 days after transurethral tumour implantation. Serial MRI
scans of TNF-α treated mice revealed significant retardation of tumour growth which correlated well with
corresponding histological examination of the whole mount bladder sections illustrating areas and depth
of tumour regression. Intravesical instillation of combination TNF-α plus IFN-γ into tumour-bearing mice
caused tumour growth inhibition up to 21 days following treatment; the results, however, were not superior
to those noted with TNF-α alone. Sequential MR images of tumour-bearing bladders following intravesical
treatment with IL-2 revealed tumour regression with no visible tumour from day 21 to 33 post tumour
implant. Histological examination revealed foci of carcinoma in situ only. Control untreated bladders
revealed deeply invasive transitional cell carcinoma. These results show that MRI offers a dependable tool
for noninvasive monitoring of tumour growth and of the course of experimental bladder tumour during
therapy. |
| format | Article |
| id | doaj-art-818f9349313f4bf08d7c66aba158f6f4 |
| institution | Kabale University |
| issn | 1180-2332 |
| language | English |
| publishDate | 1992-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Infectious Diseases |
| spelling | doaj-art-818f9349313f4bf08d7c66aba158f6f42025-02-03T01:01:34ZengWileyCanadian Journal of Infectious Diseases1180-23321992-01-013Suppl B14314810.1155/1992/510914BRM Immunotherapy of Orthotopically Implanted Murine Bladder Tumours: Treatment Response by Monitoring MRISalam A KadhimJoseph L ChinBertha M GarciaPeeyush K LalaChris J NorleyBarbara A McLeanStephen J KarlikThe authors evaluated magnetic resonance imaging (MRI) for monitoring orthotopic bladder tumour growth and treatment response to intravesical immunotherapy with the biological response modifiers (BRMs): recombinant tumour necrosis factor alpha (TNF-α), combination of TNF-α plus interferon gamma (IFN-γ) and interleukin-2 (IL-2). MRI demonstrated detection of early superficial murine bladder tumour (MBT-2) and accurate sequential assessment of the topography and depth of intravesical tumour involvement. Response to intravesical instillations with multiple doses ofBRMs was assessed against early stage MBT-2 bladder tumours (confirmed by MRI) 14 days after transurethral tumour implantation. Serial MRI scans of TNF-α treated mice revealed significant retardation of tumour growth which correlated well with corresponding histological examination of the whole mount bladder sections illustrating areas and depth of tumour regression. Intravesical instillation of combination TNF-α plus IFN-γ into tumour-bearing mice caused tumour growth inhibition up to 21 days following treatment; the results, however, were not superior to those noted with TNF-α alone. Sequential MR images of tumour-bearing bladders following intravesical treatment with IL-2 revealed tumour regression with no visible tumour from day 21 to 33 post tumour implant. Histological examination revealed foci of carcinoma in situ only. Control untreated bladders revealed deeply invasive transitional cell carcinoma. These results show that MRI offers a dependable tool for noninvasive monitoring of tumour growth and of the course of experimental bladder tumour during therapy.http://dx.doi.org/10.1155/1992/510914 |
| spellingShingle | Salam A Kadhim Joseph L Chin Bertha M Garcia Peeyush K Lala Chris J Norley Barbara A McLean Stephen J Karlik BRM Immunotherapy of Orthotopically Implanted Murine Bladder Tumours: Treatment Response by Monitoring MRI Canadian Journal of Infectious Diseases |
| title | BRM Immunotherapy of Orthotopically Implanted Murine Bladder Tumours: Treatment Response by Monitoring MRI |
| title_full | BRM Immunotherapy of Orthotopically Implanted Murine Bladder Tumours: Treatment Response by Monitoring MRI |
| title_fullStr | BRM Immunotherapy of Orthotopically Implanted Murine Bladder Tumours: Treatment Response by Monitoring MRI |
| title_full_unstemmed | BRM Immunotherapy of Orthotopically Implanted Murine Bladder Tumours: Treatment Response by Monitoring MRI |
| title_short | BRM Immunotherapy of Orthotopically Implanted Murine Bladder Tumours: Treatment Response by Monitoring MRI |
| title_sort | brm immunotherapy of orthotopically implanted murine bladder tumours treatment response by monitoring mri |
| url | http://dx.doi.org/10.1155/1992/510914 |
| work_keys_str_mv | AT salamakadhim brmimmunotherapyoforthotopicallyimplantedmurinebladdertumourstreatmentresponsebymonitoringmri AT josephlchin brmimmunotherapyoforthotopicallyimplantedmurinebladdertumourstreatmentresponsebymonitoringmri AT berthamgarcia brmimmunotherapyoforthotopicallyimplantedmurinebladdertumourstreatmentresponsebymonitoringmri AT peeyushklala brmimmunotherapyoforthotopicallyimplantedmurinebladdertumourstreatmentresponsebymonitoringmri AT chrisjnorley brmimmunotherapyoforthotopicallyimplantedmurinebladdertumourstreatmentresponsebymonitoringmri AT barbaraamclean brmimmunotherapyoforthotopicallyimplantedmurinebladdertumourstreatmentresponsebymonitoringmri AT stephenjkarlik brmimmunotherapyoforthotopicallyimplantedmurinebladdertumourstreatmentresponsebymonitoringmri |